Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
doi: 10.3389/fphys.2022.897168 Received 16 March 2022 Accepted 04 May 2022 Published 25 May 2022 Volume 13 - 2022 Edited by Carlo C
The microtiter plate provided in this kit has been pre-coated with an antibody specific to Rat GROa/CXCL1
The denaturation of proteins: The effect of denaturation on the viscosity of the solutions of certain proteins
This is to quickly increase vitamin B12 levels
269 The multilineage differentiation potential of aged HSCs is impaired, showing a bias toward myeloid differentiation (erythroid, granulocytic, and megakaryocytic lineages), whereas the differentiation ability toward lymphoid lineages (T cells, B cells) is significantly reduced
